Block Listing Return

Diaceutics PLC

05 April 2024

 

Diaceutics PLC

BLOCK LISTING RETURN

Belfast and London, 5 April 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and bitech industry industry, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the the UK and Global Share Incentive Plan for employees (the "SIP") and the Employee Share Option Plan (the "ESOP") which includes long term incentive awards.

Name of applicant:		Diaceutics PLC
Name of scheme:		UK and Global Share Incentive Plan for employees (the "SIP") and the Employee Share Option Plan (the "ESOP") which includes long term incentive awards.
Period of return:	From:	6 October 2023	To:	6 April 2024
Balance under scheme from previous return:		1,500,000 Ordinary Shares of £0.002 each
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:		N/A
Number of securities issued/allotted under schemes during period:		46,440 Ordinary Shares
Balance under scheme not yet issued/allotted at end of period		1,453,560  Ordinary Shares
Number and class of securities originally listed and the date of admission		1,500,000  Ordinary Shares on 6 October 2023
Total number of securities in issue at the end of the period		84,696,786 Ordinary Shares of £0.002 each
Name of contact:		Nick Roberts
Telephone number of contact:		As below

Enquiries:

Diaceutics PLC	Tel: [phone]
Ryan Keeling, Chief Executive Officer	[e-mail]
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: [phone]
Ben Maddison
Nick Harland
Kate Hanshaw
Alma Strategic Communications	Tel: [phone]
Caroline Forde	[e-mail]
Kinvara Verdon

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

 

END